10.04.2019 • News

Carlyle Takes Minority Stake in Cepsa

Carlyle Takes Minority Stake in Cepsa (c) Mubadala
Carlyle Takes Minority Stake in Cepsa (c) Mubadala

Funds associated with US investment group Carlyle have agreed to take a "significant" minority interest in Spanish oil & gas and chemicals company Cepsa from Abu Dhabi-based Mubadala Investment Company.

Carlyle will take a share ranging between 30% and 40%, with Mubadala remaining Cepsa’s majority shareholder. Mubadala said final stakes will be confirmed once the transaction closes, which is expected by the end of 2019, subject to the usual regulatory approvals. The companies did not disclose financial terms.

Mubadala said the agreement marks the successful conclusion of a dual-track process through a public offering and private placement to bring in new partners as part of its portfolio management strategy.

Marcel Van Poecke, head of Carlyle International Energy Partners, said Cepsa offers strong potential and future opportunities in the global energy sector.

Cepsa is also the global leader in the production of linear alkyl benzene (LAB), as well as the world's second largest producer of phenol and acetone. The Madrid-headquartered group is currently developing a 150,000 t/y LAB plant at Abu Dhabi National Oil Company's (ADNOC) complex in Ruwais, UAE, as well as upgrading its own plant in San Roque, Cadiz, Spain. The latter project, which will expand capacity by 50,000 t/y, is due online in the first half of 2020.

Virtual Event

Outsourced Biomanufacturing
Strategic Outsourcing in Biopharmaceuticals

Outsourced Biomanufacturing

April 22, 2026 | Join biopharma professionals, CDMO leaders, and supply chain innovators for a virtual event exploring the future of outsourced biomanufacturing.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read